These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34610049)

  • 1. Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screening-mHealth Screening to Prevent Strokes (mSToPS).
    Steinhubl SR; Waalen J; Sanyal A; Edwards AM; Ariniello LM; Ebner GS; Baca-Motes K; Zambon RA; Sarich T; Topol EJ
    PLoS One; 2021; 16(10):e0258276. PubMed ID: 34610049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial.
    Steinhubl SR; Waalen J; Edwards AM; Ariniello LM; Mehta RR; Ebner GS; Carter C; Baca-Motes K; Felicione E; Sarich T; Topol EJ
    JAMA; 2018 Jul; 320(2):146-155. PubMed ID: 29998336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial.
    Steinhubl SR; Mehta RR; Ebner GS; Ballesteros MM; Waalen J; Steinberg G; Van Crocker P; Felicione E; Carter CT; Edmonds S; Honcz JP; Miralles GD; Talantov D; Sarich TC; Topol EJ
    Am Heart J; 2016 May; 175():77-85. PubMed ID: 27179726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of AF Screening With 2-Week Patch Monitors: The mSToPS Study.
    Reynolds MR; Stein AB; Sun X; Hytopoulos E; Steinhubl SR; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2023 Nov; 16(11):e009751. PubMed ID: 37905421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic kidney disease and undiagnosed atrial fibrillation in individuals with diabetes.
    Heo NJ; Rhee SY; Waalen J; Steinhubl S
    Cardiovasc Diabetol; 2020 Sep; 19(1):157. PubMed ID: 32998739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke: A Post Hoc Analysis of the LOOP Randomized Clinical Trial.
    Diederichsen SZ; Frederiksen KS; Xing LY; Haugan KJ; Højberg S; Brandes A; Graff C; Olesen MS; Krieger D; Køber L; Svendsen JH
    JAMA Neurol; 2022 Oct; 79(10):997-1004. PubMed ID: 36036546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Kahwati LC; Asher GN; Kadro ZO; Keen S; Ali R; Coker-Schwimmer E; Jonas DE
    JAMA; 2022 Jan; 327(4):368-383. PubMed ID: 35076660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study.
    Halcox JPJ; Wareham K; Cardew A; Gilmore M; Barry JP; Phillips C; Gravenor MB
    Circulation; 2017 Nov; 136(19):1784-1794. PubMed ID: 28851729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial.
    Gladstone DJ; Wachter R; Schmalstieg-Bahr K; Quinn FR; Hummers E; Ivers N; Marsden T; Thornton A; Djuric A; Suerbaum J; von Grünhagen D; McIntyre WF; Benz AP; Wong JA; Merali F; Henein S; Nichol C; Connolly SJ; Healey JS;
    JAMA Cardiol; 2021 May; 6(5):558-567. PubMed ID: 33625468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of mHealth Devices to Screen for Atrial Fibrillation: Cost-Effectiveness Analysis.
    Giebel GD
    JMIR Mhealth Uhealth; 2020 Oct; 8(10):e20496. PubMed ID: 33021489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor.
    Singer DE; Atlas SJ; Go AS; Lopes RD; Lubitz SA; McManus DD; Revkin JH; Mills D; Crosson LA; Lenane JC; Aronson RS
    Am Heart J; 2022 Jul; 249():76-85. PubMed ID: 35472303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ECG-based machine learning model for predicting new-onset atrial fibrillation is superior to age and clinical features in identifying patients at high stroke risk.
    Raghunath S; Pfeifer JM; Kelsey CR; Nemani A; Ruhl JA; Hartzel DN; Ulloa Cerna AE; Jing L; vanMaanen DP; Leader JB; Schneider G; Morland TB; Chen R; Zimmerman N; Fornwalt BK; Haggerty CM
    J Electrocardiol; 2023; 76():61-65. PubMed ID: 36436476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial.
    Lubitz SA; Atlas SJ; Ashburner JM; Lipsanopoulos ATT; Borowsky LH; Guan W; Khurshid S; Ellinor PT; Chang Y; McManus DD; Singer DE
    Circulation; 2022 Mar; 145(13):946-954. PubMed ID: 35232217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.
    Yao Y; Guo Y; Lip GYH;
    JAMA Netw Open; 2021 Dec; 4(12):e2140071. PubMed ID: 34932104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
    Hobbs FD; Fitzmaurice DA; Mant J; Murray E; Jowett S; Bryan S; Raftery J; Davies M; Lip G
    Health Technol Assess; 2005 Oct; 9(40):iii-iv, ix-x, 1-74. PubMed ID: 16202350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
    Xing LY; Diederichsen SZ; Højberg S; Krieger DW; Graff C; Frikke-Schmidt R; Olesen MS; Brandes A; Køber L; Haugan KJ; Svendsen JH
    Circulation; 2023 Jun; 147(24):1788-1797. PubMed ID: 37061802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study.
    Svennberg E; Engdahl J; Al-Khalili F; Friberg L; Frykman V; Rosenqvist M
    Circulation; 2015 Jun; 131(25):2176-84. PubMed ID: 25910800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial.
    Buck BH; Hill MD; Quinn FR; Butcher KS; Menon BK; Gulamhusein S; Siddiqui M; Coutts SB; Jeerakathil T; Smith EE; Khan K; Barber PA; Jickling G; Reyes L; Save S; Fairall P; Piquette L; Kamal N; Chew DS; Demchuk AM; Shuaib A; Exner DV
    JAMA; 2021 Jun; 325(21):2160-2168. PubMed ID: 34061146
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.